Liver cancer treatment company, Sirtex Medical Limited
(ASX:SRX), has terminated the employment of its chief executive officer, Gilman Wong.
It comes following an investigation into his October 2016 share trading.
The board decided to terminate Mr Wong's contract effective immediately on Friday 13 January, after reviewing a report from legal advisers, Watson Mangioni.
Sirtex is conducting an executive search for a permanent replacement, while current Chief Operating Officer, Nigel Lange, will stand in as acting CEO.
Sirtex Medical Limited reported a net profit of $53.6 million at 30 June 2016
